Teva Pharmaceutical - PARAGARD

What Teva Pharmaceutical - PARAGARD does

Paragard is a prescription-only hormone-free intrauterine device (IUD) currently owned and manufactured by CooperSurgical, Inc., which acquired the product from Teva Pharmaceuticals in 2017. The product is a T-shaped frame composed of polyethylene and barium sulfate wrapped with a thin layer of copper, measuring 1.26 inches wide by 1.42 inches high and weighing under one gram. Copper is the sole active ingredient; it produces a localized inflammatory reaction that is toxic to sperm, yielding over 99% contraceptive efficacy for up to 10 years without affecting ovulation or natural menstrual cycles. Paragard is the only FDA-approved copper IUD marketed in the United States and has held continuous FDA approval for over 35 years.

The asset is commercialized through a B2B2C channel: OB/GYNs and trained healthcare providers place the device during routine office visits, supported by a Zocdoc doctor-locator integration for patient referrals and a self-pay option through Biologics by McKesson specialty pharmacy (1-888-275-8596). Most insured patients receive the device at no out-of-pocket cost under the Affordable Care Act, billed via J-code J7300. Target segments include women seeking hormone-free contraception, postpartum and breastfeeding women, and women with medical contraindications to hormonal birth control. The product is sold only in the United States; the official website states it is intended for US residents only. Marketing is led through paragard.com, social channels (Instagram, Facebook, YouTube), an HCP portal at hcp.paragard.com, and patient testimonials.

The principal risk factor is significant product liability exposure. Over 3,500 lawsuits alleging device fracture during removal — claimed to cause infertility, organ damage, and infections — have been consolidated into federal multidistrict litigation (MDL No. 2974) in the Northern District of Georgia, with both CooperSurgical and Teva named as defendants. The product remains FDA-approved and on the market. No financial disclosures, headcount, or pipeline announcements are available; CooperSurgical is privately held and does not separately report Paragard revenue.

Name

Teva Pharmaceutical - PARAGARD

Legal name

CooperSurgical, Inc.

Website

https://paragard.com

Company type

Private

Operating status

Operating

Short description

Paragard, owned by CooperSurgical (acquired from Teva in 2017), manufactures the only FDA-approved hormone-free copper IUD in the United States. The prescription T-shaped device provides over 99% contraceptive efficacy for up to 10 years and is sold to women through OB/GYN providers.

Ownership category

akta.pro rank

Product category

Contraceptive Medical Devices

NAICS

Family Planning Centers (621410)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

General Obstetrics (Prenatal/Antepartum Care) (HLAKAJAA)

akta.pro secondary industry

Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables) (HLAHACAF)

Keywords

• Copper IUD contraception
• Hormone-free birth control
• Intrauterine medical device
• Long-acting reversible contraception
• Prescription contraceptive device

Headquarters

HQ city

Overland Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel, Others

Revenue model

1. Prescription Medical Device Sales: Paragard generates revenue through the sale of its copper IUD as a prescription medical device. Healthcare providers administer the device during office visits. The product is covered by most insurance plans under the Affordable Care Act, with a J-code J7300 for billing purposes. For uninsured patients, self-pay options are available through Biologics by McKesson specialty pharmacy.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Paragard is a hormone-free copper intrauterine device (IUD) that prevents pregnancy for up to 10 years. It is a T-shaped polyethylene and barium sulfate frame wrapped with a thin layer of copper, placed in the uterus by a healthcare provider during a routine office visit. The product is FDA approved for over 35 years and is over 99% effective at preventing pregnancy without hormones.

Product overview

Paragard is a single-product medical device portfolio consisting of the Paragard Copper IUD, a hormone-free intrauterine device. The product is a T-shaped contraceptive made of soft flexible plastic wrapped with copper, providing up to 10 years of pregnancy prevention with over 99% effectiveness. It is positioned as the #1 prescribed hormone-free IUD and is distributed through healthcare providers, with coverage available under most insurance plans through the Affordable Care Act.

Differentiator

Problem solved

Functional benefit

Products and services

• Paragard Copper IUD A hormone-free intrauterine device (IUD) that prevents pregnancy for up to 10 years using copper as its sole active ingredient. The T-shaped device is made of polyethylene and barium sulfate wrapped with a thin layer of copper, measures 1.26 inches wide and 1.42 inches high, weighs less than 1 gram, is FDA approved for over 35 years, and is over 99% effective at preventing pregnancy. It is placed by an OB/GYN or trained healthcare provider during a non-surgical, in-office procedure and is intended for women seeking long-acting reversible contraception without hormones.

Quantifiable outcome

• Over 99% effective at preventing pregnancy
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• CooperSurgical, Inc.coreOthersCooperSurgical is the manufacturer of Paragard IUD. The company maintains the official Paragard website (paragard.com) and holds the Paragard trademark. Teva Pharmaceuticals is responsible for commercial distribution and marketing of the product.
• Biologics by McKessoncoreChannel Partner/ Reseller/ DistributorMcKesson's specialty pharmacy division serves as the designated self-pay pharmacy partner for Paragard patients without insurance coverage. Patients can contact 1-888-275-8596 to self-pay for their Paragard prescription.
• ZocdocminorGTM or Marketing PartnerDoctor locator integration allowing patients to find healthcare providers who offer Paragard IUD placement services through the Zocdoc platform.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Teva Pharmaceutical Industries: Teva was the prior owner of Paragard before selling it to CooperSurgical in 2017 and remains a co-defendant in the ongoing MDL. Operates a broader women's health and generic pharmaceutical portfolio that overlaps with Paragard's market.
• CooperSurgical (parent): CooperSurgical is the parent company that owns and operates Paragard within a broader women's health, fertility, and surgical device portfolio. Indirectly comparable as the operational entity behind the product.
• Pfizer (Depo-Provera): Pfizer markets Depo-Provera, a long-acting injectable contraceptive that competes with Paragard for women seeking reversible, non-daily hormonal contraception, providing a similar LARC-style value proposition from a large pharma incumbent.

Regional players

• Mayne Pharma (hormonal contraceptive portfolio): Mayne Pharma markets generic and branded hormonal contraceptives in the US, including oral and injectable options. It competes with Paragard for the same patient population of women seeking prescription contraception, though through different delivery formats.

Emerging players

• Mona Lisa N.V. Mona Lisa is a Belgian manufacturer of copper IUDs (e.g., Mona Lisa NT, Mini) that compete with Paragard in the same hormone-free copper IUD category internationally. Although not currently FDA-approved in the US, it represents the closest direct product analogue globally.
• Evofem Biosciences (Phexxi): Evofem markets Phexxi, a hormone-free, on-demand vaginal contraceptive gel that competes with Paragard for women seeking non-hormonal birth control options, though on a different duration and administration model.
• Sebela Pharmaceuticals: Sebela is a US-focused women's health pharmaceutical company with a contraception portfolio and is reportedly developing a new copper IUD entrant to challenge Paragard's regulatory exclusivity in the US copper IUD category.

Direct peers

• AbbVie / Allergan (Liletta): AbbVie/Allergan markets Liletta, a hormonal IUD competing head-to-head with Paragard for the same OB/GYN-prescribed LARC use case. Like Paragard, Liletta is placed in-office and reimbursed under ACA, making it a direct share competitor.
• Bayer Women's Health (Mirena/Kyleena/Skyla): Bayer manufactures the leading hormonal IUDs (Mirena, Kyleena, Skyla) that directly compete with Paragard in the US LARC category. Both target women seeking long-acting reversible contraception placed by OB/GYNs, with Bayer's hormonal products holding the largest share of the IUD market.
• Organon (Nexplanon, NuvaRing): Organon markets Nexplanon (a long-acting reversible contraceptive arm implant) and NuvaRing, which compete with Paragard for the same patient population of women seeking long-acting or convenient prescription contraception outside of daily pills.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/paragard
• Facebookfacebook.com/Paragard
• YouTubeyoutube.com/channel/paragard

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Pharmaceutical - PARAGARD